| Literature DB >> 33493696 |
Gwilym J Webb1, Ronan P Ryan2, Tom P Marshall2, Gideon M Hirschfield3.
Abstract
BACKGROUND & AIMS: The epidemiology of autoimmune liver disease (AILD) is challenging to study because of the diseases' rarity and because of cohort selection bias. Increased incidence farther from the Equator has been reported for multiple sclerosis, another autoimmune disease. We assessed the incidence of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH) in relation to latitude.Entities:
Keywords: Autoimmune Hepatitis; Autoimmune Liver Disease; Latitude; Primary Biliary Cholangitis; Primary Sclerosing Cholangitis
Mesh:
Year: 2021 PMID: 33493696 PMCID: PMC8661127 DOI: 10.1016/j.cgh.2021.01.029
Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN: 1542-3565 Impact factor: 11.382
Prevalence of PBC, PSC, and AIH in 2015
| Category | Subcategory | PBC | PSC | AIH | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Prevalence | 95% CI | n | Prevalence | 95% CI | n | Prevalence | 95% CI | ||
| Population | – | 1299 | 39.62 | 37.50–41.74 | 353 | 10.77 | 9.65–11.88 | 1116 | 34.04 | 32.06–36.02 |
| Latitude | 50°- | 83 | 28.16 | 21.88–34.44 | 27 | 9.71 | 5.87–13.55 | 93 | 32.19 | 25.38–39.00 |
| 51°- | 381 | 30.59 | 27.50–33.69 | 141 | 10.61 | 8.84–12.38 | 382 | 29.78 | 26.76–32.79 | |
| 52°- | 84 | 27.29 | 21.44–33.15 | 30 | 9.90 | 6.29–13.50 | 88 | 29.00 | 22.89–35.10 | |
| 53°- | 161 | 42.01 | 35.51–48.51 | 34 | 8.55 | 5.64–11.45 | 143 | 37.20 | 31.04–43.37 | |
| 54°- | 153 | 63.86 | 53.70–74.02 | 27 | 11.41 | 7.09–15.74 | 98 | 42.69 | 34.10–51.30 | |
| 55°- | 195 | 49.79 | 42.02–57.56 | 40 | 10.46 | 7.01–13.91 | 148 | 40.47 | 33.02–47.93 | |
| 56°- | 103 | 60.95 | 48.53–73.36 | 18 | 10.63 | 5.67–15.58 | 71 | 41.00 | 31.17–50.82 | |
| 57°- | 129 | 61.08 | 50.11–72.05 | 34 | 16.70 | 10.77–22.63 | 88 | 39.11 | 30.44–47.78 | |
| Missing | 10 | 37.40 | 15.06–59.74 | 2 | 8.51 | 0.00–19.85 | 5 | 18.50 | 3.98–33.03 | |
| Sex | Male | 143 | 8.82 | 7.37–10.28 | 205 | 13.25 | 11.43–15.07 | 283 | 17.93 | 15.83–20.04 |
| Female | 1156 | 69.35 | 65.36–73.33 | 148 | 8.69 | 7.28–10.09 | 833 | 50.36 | 46.92–53.79 | |
| Age | 0-9.9 | 0 | 0.00 | 0.00–0.00 | 1 | 0.06 | 0.00–0.18) | 2 | 2.55 | 0.00–7.43 |
| 10-19.9 | 0 | 0.00 | 0.00–0.00 | 11 | 3.64 | 1.40–5.89 | 28 | 9.02 | 4.34–13.68 | |
| 20-29.9 | 2 | 0.77 | 0.00–1.95 | 33 | 7.23 | 4.14–10.32 | 67 | 16.74 | 10.76–22.71 | |
| 30-39.9 | 31 | 5.88 | 3.78–7.98 | 42 | 8.30 | 5.72–10.88 | 82 | 23.58 | 14.76–32.40 | |
| 40-49.9 | 121 | 21.04 | 17.27–24.82 | 44 | 9.09 | 5.44–12.73 | 132 | 28.08 | 18.51–37.65 | |
| 50-59.9 | 260 | 52.81 | 41.85–63.77 | 67 | 12.34 | 9.36–15.32 | 201 | 35.66 | 30.68–40.65 | |
| 60-69.9 | 363 | 84.44 | 70.06–98.82 | 73 | 15.81 | 12.07–19.55 | 279 | 68.96 | 55.14–82.77 | |
| 70-79.9 | 344 | 100.97 | 89.93–112.02 | 54 | 19.14 | 12.56–25.72 | 221 | 66.06 | 56.93–75.20 | |
| 80-89.9 | 163 | 84.97 | 70.48–99.46 | 26 | 12.41 | 7.34–17.49 | 97 | 57.29 | 44.49–70.10 | |
| 90+ | 15 | 29.64 | 13.90–45.37 | 2 | 3.38 | 0.00–7.90 | 7 | 33.83 | 0.96–66.69 | |
| Deprivation | 1 – least | 269 | 38.15 | 32.99–43.30 | 13 | 9.84 | 6.14–13.53 | 233 | 31.40 | 26.79–36.00 |
| 2 | 295 | 43.15 | 38.50–48.36 | 88 | 11.92 | 9.67–14.69 | 261 | 35.87 | 31.40–40.34 | |
| 3 | 268 | 39.24 | 34.82–44.24 | 83 | 12.14 | 9.79–15.05 | 247 | 36.30 | 31.77–40.83 | |
| 4 | 256 | 41.82 | 37.00–47.27 | 70 | 10.25 | 8.11–12.96 | 189 | 32.09 | 27.41–36.78 | |
| 5 – most | 175 | 40.28 | 34.74–46.72 | 64 | 10.45 | 8.18–13.36 | 156 | 37.31 | 30.60–44.00 | |
| Missing | 36 | 28.32 | 20.43–39.27 | 35 | 8.06 | 5.78–11.22 | 30 | 27.27 | 16.52–38.03 | |
| Smoking | Smoker | 347 | 48.60 | 43.04–4.15 | 41 | 5.27 | 3.54–7.00 | 273 | 40.01 | 34.37–45.66 |
| Ex-smoker | 351 | 52.55 | 46.96–58.13 | 60 | 8.49 | 6.19–10.80 | 234 | 36.33 | 31.46–41.21 | |
| Never smoker | 596 | 31.43 | 28.89–33.97 | 247 | 14.13 | 12.34–15.93 | 595 | 32.73 | 29.91–35.57 | |
| Missing | 5 | 10.69 | 0.61–20.77 | 5 | 3.92 | 0.00–8.14 | 14 | 23.31 | 8.09–38.55 | |
NOTE. Figures are adjusted for latitude, sex, age, Townsend deprivation quintile, and smoking status by direct standardization as appropriate. Figures are per 100,000 population with 95% CIs. Deprivation refers to Townsend deprivation quintiles. See also Supplementary Table 4 for unadjusted figures.
AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; CI, confidence interval.
Incidence per 100,000 per Year of PBC, PSC, and AIH for the Time Period January 1, 2002 to May 10, 2016
| Category | Subcategory | PBC | PSC | AIH | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Incidence | 95% CI | n | Incidence | 95% CI | n | Incidence | 95% CI | ||
| Population | – | 1314 | 2.47 | 2.33–2.60 | 396 | 0.74 | 0.67–0.82 | 1034 | 1.95 | 1.83–2.07 |
| Latitude | 50°- | 111 | 1.96 | 1.57–2.34 | 42 | 0.76 | 0.52–1.00 | 103 | 1.80 | 1.44–2.17 |
| 51°- | 373 | 1.86 | 1.67–2.06 | 135 | 0.65 | 0.54–0.75 | 359 | 1.75 | 1.57–1.93 | |
| 52°- | 135 | 1.75 | 1.45–2.05 | 68 | 0.84 | 0.64–1.05 | 142 | 1.76 | 1.46–2.05 | |
| 53°- | 220 | 2.76 | 2.40–3.13 | 60 | 0.75 | 0.56–0.94 | 157 | 1.97 | 1.66–2.28 | |
| 54°- | 161 | 4.35 | 3.66–5.05 | 29 | 0.80 | 0.50–1.10 | 79 | 2.18 | 1.68–2.67 | |
| 55°- | 151 | 4.06 | 3.31–4.80 | 33 | 0.89 | 0.56–1.22 | 88 | 2.35 | 1.77–2.92 | |
| 56°- | 70 | 4.19 | 3.13–5.25 | 9 | 0.52 | 0.18–0.86 | 45 | 2.45 | 1.69–3.22 | |
| 57°- | 86 | 4.55 | 3.52–5.58 | 18 | 0.98 | 0.50–1.46 | 58 | 3.06 | 2.18–3.93 | |
| Missing | 7 | 2.36 | 0.57–4.15 | 2 | 0.56 | 0.00–1.33 | 3 | 0.73 | 0.00–1.57 | |
| Sex | Male | 173 | 0.66 | 0.56–0.76 | 230 | 0.91 | 0.79–1.03 | 241 | 0.94 | 0.82–1.06 |
| Female | 1141 | 4.24 | 3.99–4.49 | 166 | 0.59 | 0.50–0.68 | 793 | 2.92 | 2.72–3.13 | |
| Age, | 0–9.9 | 0 | 0.00 | 0.00–0.00 | 2 | 0.00 | 0.00–0.00 | 7 | 0.12 | 0.00–0.26 |
| 10–19.9 | 1 | 0.01 | 0.00–0.02 | 21 | 0.03 | 0.01–0.04 | 55 | 0.93 | 0.54–1.32 | |
| 20–29.9 | 5 | 0.07 | 0.01–0.13 | 34 | 0.05 | 0.03–0.07 | 48 | 0.62 | 0.44–0.81 | |
| 30–39.9 | 59 | 0.71 | 0.52–0.90 | 28 | 0.03 | 0.02–0.05 | 87 | 1.10 | 0.87–1.34 | |
| 40–49.9 | 181 | 1.94 | 1.65–2.23 | 68 | 0.08 | 0.06–0.10 | 132 | 1.45 | 1.20–1.70 | |
| 50–59.9 | 318 | 4.10 | 3.52–4.68 | 61 | 0.08 | 0.06–0.10 | 221 | 2.70 | 2.34–3.07 | |
| 60–69.9 | 353 | 5.08 | 4.53–5.63 | 87 | 0.14 | 0.10–0.17 | 239 | 3.68 | 3.13–4.23 | |
| 70–79.9 | 277 | 6.22 | 5.20–7.25 | 65 | 0.15 | 0.10–0.19 | 181 | 3.72 | 3.15–4.29 | |
| 80–89.9 | 111 | 4.28 | 3.20–5.36 | 28 | 0.09 | 0.05–0.13 | 61 | 2.34 | 1.67–3.00 | |
| ≥90 | 9 | 1.21 | 0.38–2.05 | 2 | 0.02 | 0.00–0.05 | 3 | 0.71 | 0.00–1.65 | |
| Deprivation | 1 (least) | 268 | 2.21 | 1.91–2.51 | 99 | 0.67 | 0.53–0.81 | 242 | 1.85 | 1.59–2.11 |
| 2 | 287 | 2.43 | 2.14–2.72 | 88 | 0.74 | 0.58–0.91 | 225 | 1.90 | 1.65–2.16 | |
| 3 | 282 | 2.60 | 2.29–2.91 | 87 | 0.81 | 0.64–0.98 | 219 | 2.02 | 1.75–2.29 | |
| 4 | 244 | 2.62 | 2.28–2.96 | 69 | 0.80 | 0.61–1.00 | 175 | 1.95 | 1.65–2.25 | |
| 5 (most) | 187 | 2.82 | 2.35–3.28 | 39 | 0.73 | 0.46–0.99 | 141 | 2.25 | 1.82–2.67 | |
| Missing | 46 | 2.86 | 1.93–3.79 | 14 | 0.75 | 0.35–1.15 | 32 | 1.76 | 1.06–2.45 | |
| Smoking | Smoker | 400 | 3.40 | 3.03–3.77 | 54 | 0.47 | 0.33–0.61 | 256 | 2.24 | 1.94–2.55 |
| Ex-smoker | 308 | 2.93 | 2.58–3.27 | 69 | 0.61 | 0.45–0.77 | 185 | 1.98 | 1.54–2.42 | |
| Never smoker | 596 | 1.96 | 1.80–2.12 | 265 | 0.95 | 0.83–1.07 | 578 | 1.96 | 1.79–2.12 | |
| Missing | 10 | 0.87 | 0.17–1.57 | 8 | 0.26 | 0.00–0.56 | 15 | 0.30 | 0.00–0.64 | |
NOTE. Figures are adjusted for latitude, sex, age, Townsend deprivation quintile, and smoking status by direct standardization as appropriate. Figures are per 100,000 population/y with 95% CIs. Deprivation refers to Townsend deprivation quintiles. See also Supplementary Table 2 for unadjusted figures.
AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; CI, confidence interval.
Figure 1Incidence of autoimmune liver disease by latitude. Top row: Plots denote crude incidence of (A) primary biliary cholangitis (PBC), (B) primary sclerosing cholangitis (PSC), and (C) autoimmune hepatitis (AIH). (D–F) Bottom row: Plots denote adjusted incidence after adjustment for sex, age, smoking status, and Townsend deprivation quintile. For PBC and AIH there was a significant increase in incidence at more northerly latitudes both before and after adjustment; for PSC a significant correlation was not present.
Figure 2Maps of the United Kingdom showing the crude incidence of autoimmune liver diseases. Incidences are for the whole study period and shown as cases per 100,000/y. The density of shading corresponds to incidence as denoted in each panel: (A) primary biliary cholangitis (PBC), (B) primary sclerosing cholangitis (PSC), and (C) autoimmune hepatitis (AIH). The locations of major cities are shown for reference.
Figure 3Prevalence of autoimmune liver disease by latitude. Top row: Plots denote crude prevalence at the end of 2015 of (A) primary biliary cholangitis (PBC), (B) primary sclerosing cholangitis (PSC), and (C) autoimmune hepatitis (AIH). (D–F) Bottom row: Plots denote adjusted incidence after adjustment for sex, age, smoking status, and Townsend deprivation quintile. For PBC, 5.89 (2.51–9.27) per 100,000 per degree (r2 = 0.752; P = .005); PSC, 0.62 (-0.18 to 1.41) per 100,000 per degree (r2 = 0.375; P = .107); and AIH, 1.92 (0.150–3.69) per 100,000 per degree (r2 = 0.540; P = .038).